These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16019860)

  • 1. Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin.
    Hahn CA; Jones EL; Blivin JL; Sanders LL; Yu D; Dewhirst MW; Secord AA; Prosnitz LR
    Int J Hyperthermia; 2005 Jun; 21(4):349-57. PubMed ID: 16019860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer.
    Alvarez Secord A; Jones EL; Hahn CA; Petros WP; Yu D; Havrilesky LJ; Soper JT; Berchuck A; Spasojevic I; Clarke-Pearson DL; Prosnitz LR; Dewhirst MW
    Int J Hyperthermia; 2005 Jun; 21(4):333-47. PubMed ID: 16019859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma.
    Jones E; Alvarez Secord A; Prosnitz LR; Samulski TV; Oleson JR; Berchuck A; Clarke-Pearson D; Soper J; Dewhirst MW; Vujaskovic Z
    Int J Hyperthermia; 2006 Mar; 22(2):161-72. PubMed ID: 16754599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
    Bezjak A; Tu D; Bacon M; Osoba D; Zee B; Stuart G; Roy JA; Piccart M; Eisenhauer E
    J Clin Oncol; 2004 Nov; 22(22):4595-603. PubMed ID: 15466785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trial.
    Kouloulias VE; Dardoufas CE; Kouvaris JR; Gennatas CS; Polyzos AK; Gogas HJ; Sandilos PH; Uzunoglu NK; Malas EG; Vlahos LJ
    Clin Cancer Res; 2002 Feb; 8(2):374-82. PubMed ID: 11839652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy.
    von Gruenigen VE; Frasure HE; Jenison EL; Hopkins MP; Gil KM
    Gynecol Oncol; 2006 Oct; 103(1):120-6. PubMed ID: 16556458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
    Rose PG
    Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19.
    Liu J; Tu D; Dancey J; Reyno L; Pritchard KI; Pater J; Seymour LK
    Breast Cancer Res Treat; 2006 Dec; 100(3):263-71. PubMed ID: 16823511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.
    Coleman RL; Gordon A; Barter J; Sun S; Rackoff W; Herzog TJ
    Oncologist; 2007 Jan; 12(1):72-8. PubMed ID: 17227902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective quality of life study in patients with locally advanced prostate cancer, treated with radiotherapy with or without regional or interstitial hyperthermia.
    Van Vulpen M; De Leeuw JR; Van Gellekom MP; Van Der Hoeven J; De Graeff A; Van Moorselaar RJ; Van Der Tweel I; Hofman P; Lagendijk JJ; Battermann JJ
    Int J Hyperthermia; 2003; 19(4):402-13. PubMed ID: 12850926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported impact of urinary incontinence--results from treatment seeking women in 14 European countries.
    Monz B; Pons ME; Hampel C; Hunskaar S; Quail D; Samsioe G; Sykes D; Wagg A; Papanicolaou S
    Maturitas; 2005 Nov; 52 Suppl 2():S24-34. PubMed ID: 16297579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
    Garcia AA; Roman L; Muderspach L; O'meara A; Facio G; Edwards S; Burnett A
    Cancer Invest; 2005; 23(8):665-70. PubMed ID: 16377584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
    Addeo R; Faiola V; Guarrasi R; Montella L; Vincenzi B; Capasso E; Cennamo G; Rotundo MS; Tagliaferri P; Caraglia M; Del Prete S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):285-92. PubMed ID: 17922275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
    Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
    Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy.
    Truong PT; Berthelet E; Lee JC; Petersen R; Lim JT; Gaul CA; Pai H; Blood P; Ludgate CM
    Can J Urol; 2006 Jun; 13(3):3139-46. PubMed ID: 16813705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
    Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
    Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic venous disease: health status of a population and care impact on this health status through quality of life questionnaires.
    Guex JJ; Myon E; Didier L; Nguyen Le C; Taieb C
    Int Angiol; 2005 Sep; 24(3):258-64. PubMed ID: 16158036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
    Carey MS; Bacon M; Tu D; Butler L; Bezjak A; Stuart GC
    Gynecol Oncol; 2008 Jan; 108(1):100-5. PubMed ID: 17920108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral mucositis and quality of life of Hong Kong Chinese patients with cancer therapy.
    Cheng KK
    Eur J Oncol Nurs; 2007 Feb; 11(1):36-42. PubMed ID: 17258505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.